FDA Health Services Administration Telemedicine 
Bill of Health
NOVEMBER 15, 2023
DEA has done little to reduce the appearance of agency capture by the Opioid Treatment Program (OTP) industry, while FDA was years behind the evidence in approving over-the-counter naloxone. Code § 1701 et seq.
Health Law Advisor
MARCH 7, 2023
The proposed rules are more restrictive than the DEA emergency waivers under which providers conducted telemedicine prescribing for the last three years, but are less restrictive in comparison to the pre-PHE regulations applicable to telemedicine prescribing of controlled substances under the federal Controlled Substances Act (“CSA”).
Healthcare Law Today
NOVEMBER 9, 2022
Prior to the federal COVID-19 Public Health Emergency (PHE), to initiate treatment with buprenorphine at an OTP, a practitioner needed to perform a complete in-person physical evaluation. The covered benefit includes MAT for patients with OUD, a leading treatment modality that combines prescribing FDA-approved medication (e.g.,
Expert insights. Personalized for you.
173 
Let's personalize your content